|
1 |
05 01 2026 |
Panel asks Ayush Ministry to seek further extension of schemes including NAM |
Pharmabiz |
India |
|
2 |
05 01 2026 |
Haryana FDA issues strict directive on labelling & sale of high-risk industrial-grade solvents & excipients |
Pharmabiz |
India |
|
3 |
05 01 2026 |
AYUSH gets recognition in India's free trade pacts with Oman, New Zealand |
Health world (Economic Times) |
India |
|
4 |
03 01 2026 |
Govt. proposes stricter control on syrup seeks removal from Schedule K |
Medical Dialogues |
India |
|
5 |
03 01 2026 |
Indian Pharmacopoeia 2026 adds 121 New Monographs including Blood component standards |
Medical Dialogues |
India |
|
6 |
03 01 2026 |
Leadership Change at DoP :Senior IAS Officer Manoj Joshi takes Charge as Pharma Secretary |
Medical Dialogues |
India |
|
7 |
03 01 2026 |
NPPA Committee Caps price of Akums's Cetirizine Eye Drops at Rs.14.42 per ml |
Medical Dialogues |
India |
|
8 |
03 01 2026 |
Haryana & Telangana begin crackdown on nimesulide above 100 mg in immediate-release dosage forms |
Pharmabiz |
India |
|
9 |
03 01 2026 |
Commerce ministry launches market access support under EPM-NIRYAT DISHA to boost exports |
Pharmabiz |
India |
|
10 |
03 01 2026 |
DoP calls for proposals for two sub-schemes under strengthening of medical device industry |
Pharmabiz |
India |
|
11 |
03 01 2026 |
Local manufacturing is not just a priority— it is a national commitment |
Express Pharma |
India |
|
12 |
02 01 2026 |
Pharma industry, exporters to discuss PLI scheme for APIs with Korea to attract investment in 2026 |
Pharmabiz |
India |
|
13 |
02 01 2026 |
Year 2026 marks inflection point for pharma & medtech sectors as cos go for non-invasive drug delivery solutions |
Pharmabiz |
India |
|
14 |
02 01 2026 |
DoP includes member of HTAIn in expert committee on pricing of drugs |
Pharmabiz |
India |
|
15 |
02 01 2026 |
Pharma industry leaders spotlight quality, sustainability and market diversification as export priorities for 2026 |
Pharmabiz |
India |
|
16 |
02 01 2026 |
Himachal pharma industry on edge as Schedule M deadline ends |
The tribune India |
India |
|
17 |
02 01 2026 |
Aurobindo Pharma acquire branded non-oncology prescription business of Khandelwal Labs for Rs.325 crore. |
Times of India |
India |
|
18 |
02 01 2026 |
Vizag rising: Shaping India’s pharma future |
Express Pharma |
India |
|
19 |
02 01 2026 |
Pharma companies overcharged consumers by ₹10,000 crore despite price controls: data |
English Gujarat Samachar |
India |
|
20 |
02 01 2026 |
Pre-Budget Expectations: GST Simplifications Key to Pharma and Life Sciences Growth |
Biospetrum |
India |
